{"nctId":"NCT01747915","briefTitle":"A Safety, Efficacy and Tolerability Trial of Pregabalin as Add-On Treatment in Pediatric and Adult Subjects With Primary Generalized Tonic-Clonic (i.e., Grand Mal) Seizures.","startDateStruct":{"date":"2013-04-03","type":"ACTUAL"},"conditions":["Generalized Tonic Clonic Seizures"],"count":219,"armGroups":[{"label":"Study Drug Level 1","type":"EXPERIMENTAL","interventionNames":["Drug: Pregabalin Dose Level 1"]},{"label":"Study Drug Level 2","type":"EXPERIMENTAL","interventionNames":["Drug: Pregabalin Dose Level 2"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo"]}],"interventions":[{"name":"Pregabalin Dose Level 1","otherNames":["Lyrica Dose Level 1"]},{"name":"Pregabalin Dose Level 2","otherNames":["Lyrica Dose Level 2"]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Seizures classified as Primary Generalized Tonic Clonic Seizures\n* Must have at least 1 PGTC seizure in the 8 weeks prior to screening\n* Must have a minimum of 3 PGTC seizures during the 8-week baseline phase and at least 1 PGTC in each 4-week period of the baseline phase\n* Currently receiving adequate and stable dosage of 1 to 3 anti-epileptic treatments (stable within 28 days of screening)\n* Signed informed consent and assent if a minor\n* Ability to comply with daily seizure and dosing diary requirements and all study procedures\n\nExclusion Criteria:\n\n* A current diagnosis of febrile seizures, or seizures related to an ongoing acute medical illness\n* Focal seizures (simple partial, complex partial, or partial becoming secondarily generalized)\n* Status Epilepticus within 1 year prior to screening\n* Lennox-Gastaut syndrome, infantile spasms, Benign Epilepsy with Centrotemporal Spikes (BECTS) and Dravet syndrome\n* Seizures related to drugs, alcohol, or acute medical illness\n* Any change in anti-epileptic treatment regimen (type of medication or dose; VNS alteration) within 28 days of the screening visit or during the baseline phase\n* Progressive or potentially progressive structural CNS lesion or a progressive encephalopathy.\n* Progressive inborn errors of metabolism.","healthyVolunteers":false,"sex":"ALL","minimumAge":"5 Years","maximumAge":"65 Years","stdAges":["CHILD","ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Log-transformed (Log) 28-day Seizure Rate for All Primary Generalized Tonic-Clonic (PGTC) Seizures During 12-Week Double-Blind Treatment Phase","description":"All PGTC seizures experienced during treatment phase were recorded by the participants or their parents/legal guardian in a daily seizure diary. 28-day seizure rate for all PGTC seizures= (\\[number of seizures in the double blind treatment phase\\] divided by \\[number of days in double blind treatment phase minus {-} number of missing diary days in treatment phase\\])\\*28. For log-transformation, the quantity 1 was added to the 28-day seizure rate for all participants to account for any possible \"0\" seizure incidence. This resulted in final calculation as: log transformed (28-day seizure rate +1).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.17","spread":"0.097"},{"groupId":"OG001","value":"1.13","spread":"0.095"},{"groupId":"OG002","value":"1.14","spread":"0.098"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With at Least 50 Percent (%) or Greater Reduction From Baseline in 28-day Primary Generalized Tonic-clonic (PGTC) Seizure Rate During the 12-Week Double-blind Treatment Phase","description":"Percentage of participants with 50% or greater reduction from baseline in 28-day seizure rate during the 12 week double blind treatment phase were reported. 28-day seizure rate for all PGTC seizures= (\\[number of seizures in the double blind treatment phase\\] divided by \\[number of days in double blind treatment phase minus {-} number of missing diary days in treatment phase\\])\\*28.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"41.3","spread":null},{"groupId":"OG001","value":"38.9","spread":null},{"groupId":"OG002","value":"41.7","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":2,"n":75},"commonTop":["Dizziness","Headache","Somnolence","Fatigue","Upper respiratory tract infection"]}}}